Aeolus soars on BARDA contract. Cynosure jumps on earnings report. After the bell: Medivation reports positive trial results, Discovery Labs falls on offering Print E-mail
By BioMedReports.com Staff   
Tuesday, 15 February 2011 20:25
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 15, 2011.

After the bell, shares of Discovery Laboratories, Inc. (Nasdaq:DSCO) fell after the company announced that it intends to offer shares of its common stock warrants in an underwritten public offering.

Shares fell 34 cents or 11.5% to $2.60.

After hours, Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) announced the publication of data from a clinical trial evaluating the pharmacokinetics, safety and tolerability of a rapid infusion of Caldolor (ibuprofen) Injection compared to oral ibuprofen. The study, which was published in the January issue of American Journal of Health-System Pharmacy, demonstrated that the maximum plasma concentration of IV ibuprofen when administered over five to seven minutes was approximately twice that of oral ibuprofen. In addition, the time to the maximum plasma concentration of IV ibuprofen was 6.5 minutes compared with 1.5 hours for oral ibuprofen. The study results indicated that the rapid infusion of IV ibuprofen was both safe and well tolerated.

Also after the bell, Medivation, Inc. (NASDAQ:MDVN) and Astellas Pharma Inc. announced positive, new, long-term follow-up data from the Phase 1-2 trial of MDV3100 in patients with advanced prostate cancer. MDV3100 is a novel, triple-acting, oral androgen receptor antagonist. These new results showed that MDV3100 continues to show durable anti tumor activity as evaluated by median times to prostate-specific antigen (PSA) progression and radiographic progression. These findings confirm the initial Phase 1-2 results published in The Lancet, in which MDV3100 consistently demonstrated anti-tumor activity in both chemotherapy-naïve and post-chemotherapy patients across endpoints, as evaluated by PSA levels, radiographic findings and circulating tumor cell (CTC) counts.

Earlier Tuesday:

Aeolus Pharmaceuticals, Inc. (OTC:AOLS.ob), a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (ARS).

Under terms of this cost plus, fixed fee development contract, Aeolus will receive $10.4 million in the first year base period of performance and up to an additional $107.5 million in options , if exercised by BARDA, for a total contract value of up to $118 million.

Shares of Aeolus shot up 19 cents or 25% to $0.94.

Shares of Cynosure, Inc. (Nasdaq:CYNO) jumped more than 14% today after the company announced financial results for the three months and year ended December 31, 2010. The cosmetic treatment equipment maker, reported a smaller loss for the fourth quarter, reporting a net loss of $798,000, or 6 cents per share, in the three months that ended Dec. 31 which compares to a net loss of $14.5 million, or $1.14 per share, in the final quarter of 2009. The company said that revenue increased 16 percent to $22.3 million from $19.3 million. The company said annual revenue rose to $81.8 million from $72.8 million a year ago and reported a full year, net loss of $5.5 million, or 44 cents per share, which compared to a loss of $22.8 million, or $1.79 a share a year ago.

"Higher product demand from North America and overseas drove our revenue growth in the fourth quarter," said Cynosure President and Chief Executive Officer Michael Davin. "In North America, laser product sales were up 17 percent from the same period in 2009. Although financing remains difficult for many aesthetic practitioners, the relationships we have established with certain financial institutions and third-party financing sources are gradually beginning to improve access to credit for our customers. International laser product sales rose 18 percent from the fourth quarter of 2009, paced by solid gains in our Asian direct distribution network."

Shares of Cynosure gained $1.73 to $13.68.

ArthroCare Corp. (NASDAQ:ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the FDA for its Spartan 5.5 Needled Anchor. Spartan is a preloaded threaded anchor indicated for use in fixation of soft tissue to bone, such as during a rotator cuff repair. The needled version is utilized for open repairs, whereas the non-needled version, for which FDA clearance has previously been received, is for arthroscopic repairs.

Alkermes, Inc. (NASDAQ: ALKS) today announced positive preliminary results from a phase 2, double-blind, randomized, placebo-controlled clinical study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced bowel dysfunction (OBD), which includes constipation and associated gastrointestinal (GI) abnormalities resulting from chronic use of opioid pain medications. Data from the study showed that ALKS 37 significantly improved GI motility and increased the frequency of bowel movements in patients with OBD, while simultaneously preserving the analgesic effects of opioid treatment. The study also demonstrated that ALKS 37 was generally well tolerated with limited systemic exposure and bioavailability. Based on these results, Alkermes plans to advance ALKS 37 into a pivotal development program in mid calendar 2011.

Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), innovator and developer of products based upon the Microcyn® Technology platform, announced today that the company has formed a broad multi-year collaboration with Amneal Enterprises, an affiliation of independent pharmaceutical marketing, discovery and development companies, to realize the development and commercial potential of Microcyn Technology.

Chirag Patel, Co-Chairman of Amneal Enterprises, said, "We are deeply impressed by the wide importance and potential of Oculus’ Microcyn Technology and are excited by the prospects of what our strategic, organizational and financial collaboration can accomplish."

Shares of Oclulus gained 18 cents or nearly 9% on the news.

Also Tuesday:

Abbott (NYSE:ABT)
will present at the 2011 RBC Capital Markets' Healthcare Conference on Thursday, March 3, 2011.

Aethlon Medical, Inc. (OTC Bulletin Board:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it will present at the Wall Street Analyst Forum 22nd Annual Investor Conference on Tuesday, March 1, 2011 at 9:05 A.M. (EST).

Echo Therapeutics, Inc. (OTC Bulletin Board:ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced the appointment of William F. Grieco and James F. Smith to its Board of Directors.

Endologix, Inc. (Nasdaq:ELGX), developer of minimally invasive treatments for aortic disorders, announced today the presentation of the initial clinical results from the PEVAR Trial at the 2011 iCON (International Congress of Endovascular Specialists) annual meeting in Scottsdale, Arizona.

Entest BioMedical Inc. (OTCBB: ENTB) announced the Company has entered into escrow on the proposed purchase of a veterinary hospital located in Southern California pursuant to a Letter of Intent entered into on February 11, 2011.

GeckoSystems Intl. Corp. (PINKSHEETS:GOSY), a dynamic leader in the development and usage of "Mobile Robot Solutions for Safety, Security and Service"™ for the emerging mobile robotics industry, announced today that development of its GeckoNav™ Wheelchair Kit upgrade for power wheelchairs may have dramatic benefits for many primary caregivers and their elderly parents in assisted care facilities.

Gen-Probe Incorporated (Nasdaq:GPRO) announced today that its board of directors has authorized the repurchase of up to $150 million of the Company's common stock over the next year.

Given Imaging Ltd. (NASDAQ: GIVN) today announced financial results for the fourth quarter and twelve months ended December 31, 2010.

HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) will release financial results for the fourth quarter and year ended December 31, 2010 prior to the open of the U.S. stock markets on Thursday, February 24, 2011.

Gen-Probe Incorporated (Nasdaq:GPRO) today reported financial results for the fourth quarter and full year 2010, highlighted by record non-GAAP earnings per share (EPS) of $0.61 in the quarter, 17% higher than in the prior year period.

Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, will release its fourth quarter and year end 2010 financial results on Thursday, February 24, 2011 before the financial markets open.

Luminex Corporation (Nasdaq:LMNX) announced today that it has teamed with Partners HealthCare toward the discovery of novel biomarkers and development of clinical assays.

Neuralstem, Inc. (NYSE Amex:CUR) announces the appointment of business leader Stanley I. Westreich to its Board of Directors.

Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES), Dr. Claude Poulin CEO is pleased to announce to its shareholders that the board of directors have voted to accept the 15 cent offer.

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) a developer of alternative drug delivery systems, announced today that its Director of Medical Affairs, Roy Eldor, M.D., was chosen to lecture at the Fourth International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) to take place in London, England on February 16-18, 2011.

Palatin Technologies, Inc. (NYSE Amex:PTN) a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its second quarter ended December 31, 2010.

Salus Labs International (PINKSHEETS: IPEX), announced a major breakthrough by signing a Project Cooperation Agreement with Chongqing Pharmaceutical Company, one of a government-owned family of companies earning, in excess of 5 billion dollars worldwide in 2010.

Savanna East Africa, Inc. (PINKSHEETS:NVAE) (OTCQB: NVAE) today announced newly appointed Chief Executive Officer, Lieutenant Colonel (Retired) Randell Torno will travel to Nairobi, Kenya to review and advance the Company's interests in East Africa.LTC Torno departs tomorrow with an extensive agenda topped with advancing the Company's multiple pending acquisitions.

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) is pleased to announce its wholly owned subsidiary Preferred Distribution, Inc. has been approved in the State of Louisiana for its out of state wholesale pharmaceutical distribution license.

SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories announced today that SOHM, India has received confirmation of a purchase order to supply 10 different generic drug formulations in Sri Lanka.

Talecris Biotherapeutics Holdings Corp. (Nasdaq:TLCR) announced today that NASDAQ has removed TLCR from the NASDAQ Biotechnology Index(R) (Nasdaq: NBI) in anticipation of the company's pending acquisition by Grifols S.A. The change takes effect Feb. 15 prior to the market's opening.

Transgenomic, Inc. (OTC Bulletin Board:TBIO) today announced that Craig Tuttle, president and chief executive officer, will deliver the Company's corporate presentation at Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-line Forum on Thursday, February 17, 2011 at 11:30 a.m. Eastern time.

Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced an agreement to exclusively supply Menarini Diagnostics with the new Premier Hb9210 (PDx) instrument for distribution in European territories.

United Therapeutics Corporation (Nasdaq:UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2010.

 

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter